The rapid global aging of the population has heightened the clinical importance of sarcopenia, an interdisciplinary condition characterized by the progressive and widespread decline in skeletal muscle mass, strength, and function. Now formally recognized as a distinct muscle disease, sarcopenia is a key contributor to frailty, physical disability, and increased healthcare use among older adults. While current research encompasses diverse epidemiological and biological perspectives, the integration of multi-system interactions—such as the gut-muscle axis and immune-muscle crosstalk—within clinical assessment remains a vital area of exploration.This review examines the interplay between etiology, molecular pathogenesis, and contemporary diagnostic standards to characterize the syndrome’s complexity. Global prevalence escalates significantly in institutionalized populations or those over age 80. Pathogenesis is rooted in a disruption of protein homeostasis where catabolic pathways, such as the ubiquitin-proteasome system, overwhelm anabolic signaling—a process triggered by mitochondrial dysfunction, chronic low-grade inflammation, and declining sex hormones. Furthermore, the synthesis of diagnostic protocols from international consortia highlights the transition to strength-priority models to better predict the falls, fractures, and cardiovascular events. Despite significant diagnostic progress, more longitudinal research is necessary to refine population-specific cut-off criteria and identify reliable clinical biomarkers. By consolidating current mechanistic evidence and epidemiological trends, this review shows the necessity for the unified diagnostic protocol and calls for continued interdisciplinary research to improve early detection and preserve physical independence in aging societies.
This review article analyses current understanding of the role of the gut microbiome in the development of cardiovascular diseases. The gut microbiome is considered a complex environmental system involved in the regulation of metabolic, immune and inflammatory pathways that are directly relevant to cardiovascular function. Disorders in the composition and functional activity of the microbiome (dysbiosis) are associated with changes in the production of bacterial metabolites that can affect lipid metabolism, vascular tone, haemostasis and systemic inflammation. Special attention is given to the microbiome as a dynamic metabolic organ that modulates risks via the “gut-heart” axis.The article presents a detailed review of the role of important microbial metabolites, including trimethylamine N-oxide, short-chain fatty acids, and bile acid metabolites, in the pathogenesis of atherosclerosis and atherothrombosis. It is demonstrated that increased levels of trimethylamine N-oxide are associated with endothelial dysfunction, thrombocyte activation, and an increased risk of thrombotic complications, while a deficiency of short-chain fatty acids in dysbiosis contributes to an enhanced inflammatory response and disorders of vascular homeostasis. A special focus is on the relationship between the gut microbiome and bile acid metabolism and lipid metabolism regulation. The effects of new metabolites, such as phenylacetylglutamine, on adrenergic signaling and thrombus formation were investigated.It is observed that the combination of changes caused by dysbiosis constitutes a pathophysiological process involving chronic low-grade systemic inflammation, endothelial dysfunction, and increased platelet activity, thereby creating conditions conducive to the development of atherosclerosis and associated clinical complications, particularly myocardial infarction and ischemic stroke. Effects on the microbiome are a perspective area for prevention and treatment of cardiovascular diseases, therefore further researches are needed to confirm the cause-and-effect relationships.